High Content Screening Market Growing Trade among Emerging Economies Opening New Opportunities by 2026

High-content screening is a technique that is increasingly being utilised in drug development and preclinical research to identify materials such as tiny compounds, proteins, or RNA that alter the genetic output of cells in the desired way. Cells that do not respond to a medicine are often screened out due to their inability to absorb it, and the scientist hunting for a new one must look elsewhere. This is why high-activity chemicals, such as cancer, AIDS, and infectious disease treatments, are used in screenings on a regular basis. In terms of regional effect, North America has a promising future in the high content screening industry. This could be attributed to rising cases of chronic diseases and the rapidly growing geriatric population across the region. On the contrary, Asia Pacific is registering significant traction with growing disposable incomes across the region.

High content screening is most commonly used to find and analyse components with unknown roles in eukaryotic and prokaryotic cells. Cells are typically grown in growth medium treated with a range of different amounts of various chemicals for this purpose. Growing cases of neurological illnesses such as Parkinson's disease, Alzheimer's disease, and others are one of the primary drivers driving market expansion. According to the Alzheimer's Association, around 6.2 million people in the United States aged 65 and up will have Alzheimer's dementia by 2021.As per the Parkinson’s Foundation, around 60,000 people in the U.S. are diagnosed with Parkinson’s disease. This, in turn, has increased the adoption of high content screening in the drug discovery of the aforementioned disorders. Hence, such factors can stimulate growth of the high content screening market.

Another major use of high content screening is in the field of drug development. When a compound is discovered which is capable of affecting a human cell, it is then tested on animals in order to see if the results are the same as the results in humans. However, lower adoption of HCS instruments due to their expensive prices could pose several challenges in the development of the market. Besides, a dearth of skilled personnel to operate high content screening instruments and inadequate infrastructure and funding for R&D in emerging economies could potentially impede growth of the high content screening market.